This site uses cookies to improve your browsing experience. By using this site, you agree to their use. Cookie Information

Let's collaborate Boehringer Ingelheim

ASCO, Chicago, IL, USA, 1-5 June 2018

First-in-human Phase I trial of BI 836880, a vascular endothelial growth factor/angiopoietin-2-blocking Nanobody®, given every 3 weeks in patients with advanced/metastatic solid tumors

Christophe Le Tourneau, Rainer Claus, Francesco Ricci, Björn Hackanson, Christoph Rummelt, Oliver Fietz, Thomas Arnhold, Dooti Roy, Zohra Oum’Hamed, Ralph Fritsch

Le Tourneau et al ASCO 2018 poster

DLT Definitions

DLT Definition

Related information

ASCO 2018

Find information on Boehringer Ingelheim's clinical data and activities at ASCO 2018

 

VEGF/Ang2 inhibitor

BI 836880 is a humanised bispecific nanobody® comprising blocking domains for both VEGF and Ang2
Back to top

FOR HEALTHCARE PROFESSIONALS ONLY.

 

In the European Union, afatinib is approved for use in TKI-naive adults with locally advanced or metastatic NSCLC with activating EGFR mutations and in patients with NSCLC of squamous histology on or after chemotherapy. It is not yet approved in other indications.